Interview Questions with Victor E. Velculescu

 

  1. Integration of Liquid Biopsies:

“Given the rapid advancements in liquid biopsy technologies, including your development of DELFI, how do you envision their integration into routine clinical practice? Considering the current limitations, what specific innovations do you believe are necessary to overcome these hurdles, and how do you see the role of interdisciplinary collaboration in achieving these breakthroughs?”

Until recently, liquid biopsies were considered expensive, logistically complex, and used a needle-in-a-haystack approach to search for specific genetic sequence changes or methylation patterns.  We have developed a new AI liquid biopsy approach based on genome-wide fragmentomics, the discovery that cancer cells are more chaotic than normal cells and, when they die, leave behind tell-tale patterns and characteristics of cell-free DNA (cfDNA) fragments in the blood.  This new machine-learning fragmentome approach called DNA EvaLuation of Fragments for early Interception (DELFI) provides a sensitive and accessible next-generation liquid biopsy approach for early cancer detection.   As described in our recent study (Cancer Discovery, 2024) this approach has been clinically validated as a liquid biopsy test for lung cancer, a cancer type that we know benefits from early detection and yet less than six percent of eligible individuals are currently getting screened.  To be successful clinically, any new liquid biopsy test providers will have to work closely with all members of health system teams, including primary care, pulmonology, oncology, radiology, phlebotomy, and nursing staff.  I am optimistic that a new generation of AI liquid biopsy approaches that are affordable and accessible will revolutionize early cancer detection in the US and around the world. 

  1. Translating Genomic Discoveries into Therapies:

“Your research has unveiled novel genes involved in neoplasia, such as PIK3CA. What are the most significant obstacles in translating these genomic insights into actionable therapeutic targets? How do you propose we address the biological complexity and variability among patients to ensure these therapies are both effective and personalized?”

In the mid 2000’s we performed the first genome-wide sequence analysis of human cancers.  These analyses revealed a variety of driver genes and pathways not previously known to be involved in tumorigenesis.  These discoveries included PIK3CA, one of the most commonly altered genes in cancer, among others, and revealed the complex landscape of genomic changes in individual tumors.  These observations paved the way for personalized approaches to cancer patients, including new FDA approved therapies against PI3K and IDH1, and FDA approved diagnostic tests for comprehensive tumor profiling. Although challenges remain in developing effective therapies against cancer, understanding the genomic landscape of these diseases for every patient marks an important step in matching each patient with the right therapy.  I expect over time, a combination of new targeted and immune therapies, tailored to an individual’s genomic alterations will be essential to providing effective personalized therapies. 

 

  1. Cost-Effectiveness and Overdiagnosis in Liquid Biopsies:

“Precision medicine based on liquid biopsies holds immense promise, but there are concerns about cost-effectiveness and potential for overdiagnosis. In the context of global healthcare disparities, how do you propose making liquid biopsies accessible and reliable across different economic settings? What measures can be taken to mitigate the risk of overdiagnosis while maximizing early detection benefits?”

We set out some time ago to develop a liquid biopsy approach that would be high performing and widely accessible.  The effort led to developing an AI fragmentome platform which is inherently lower cost than first-generation liquid biopsy approaches.  This method uses simple lab processes and low-coverage whole genome sequencing and has lower costs than conventional liquid biopsy methods which historically have required complex chemistries and ultra-deep sequencing.  The fragmentome approach results in millions of genome-wide data points that are captured in a cfDNA fragmentation profile which when combined with AI analyses provide highly sensitive algorithms for distinguishing those with cancer from those without.  These low laboratory costs combined with high performance make this approach well suited for broad public health efforts like cancer screening in the US and globally. 

One way we can avoid overdiagnosis in cancer screening is to focus on detecting cancer types where we know screening saves lives.  In these settings, the diagnostic pathways are well established and the problem is rather that not enough people are getting screened.  As an example, we chose to focus on early detection of lung cancer as this is the greatest cancer killer in the US.  Unfortunately less than 6% of eligible individuals at risk of this disease are screened using low-dose computed tomography (CT) imaging.  The clinically validated fragmentome blood test for lung cancer will help more at risk individuals get screened.  As the next step after a positive blood test is a low-dose CT scan that is recommended in this population, and there is no risk for overdiagnosis.  We estimate that even a modest uptake of this approach will save thousands of lives in the US over the next five years. 

  1. Leveraging Transcriptomics for Personalized Treatment:

“As a pioneer in transcriptomics, you’ve shaped our understanding of cancer at the molecular level. Given the rapid pace of advancements in this field, what are the next big leaps you anticipate in transcriptomic research? How can we leverage emerging technologies, such as single-cell sequencing and spatial transcriptomics, to further refine personalized treatment regimens and improve patient outcomes?”

One of the completely unanticipated connections that have emerged recently has been the intersection between the “transcriptome”, or the compendium of transcripts representing the expressed genes in a cell, and the detection of these changes through alterations in cell-free DNA (cfDNA).  It turns out that the genome-wide cfDNA “fragmentome”, which represents the compendium of changes in cfDNA fragments, can capture changes that are occurring as a consequence of gene expression.  These include alterations in cfDNA fragmentation at sites of transcription factors as well as at regions of other epigenetic changes such as methylation, histone modification, or larger scale chromatin changes.  I believe that in the future, this connection between the transcriptome and fragmentome may provide new noninvasive ways to identify personalized therapies and mechanisms of resistance for cancer patients and improve outcomes. 

 

  1. Broader Applicability of DELFI Technology:

“While DELFI shows promise for lung cancer screening, its potential application for other cancers, especially those lacking established screening methods, remains a critical area of interest. What are the unique challenges you face in adapting DELFI for these cancers, and how do you foresee integrating AI and machine learning to enhance its diagnostic accuracy and broaden its applicability?”

The DELFI approach was built to solve population health problems.  The application of AI to genome-wide cell-free DNA (cfDNA) fragmentation profiles has provided a cost-efficient platform that is ideally suited to cancer detection in various applications.  Our platform uses millions of data points to sensitively identify individuals who may have cancer, including early-stage disease, and the cancer’s tissue of origin. Beyond our clinically validated test for detection of lung cancer, other applications of the approach include early detection of liver cancer (published in Cancer Discovery in 2023), detection of other cancer types (as described in our original Nature study in 2019 and in other studies currently underway), and monitoring therapeutic response or resistance of patients with cancer to targeted and immunotherapy.   Most recently, at the AACR 2024 meeting this year, I presented findings from a study using fragmentomics for early detection of ovarian cancer, the fifth leading cause of cancer death in the U.S.  This is an incredibly deadly disease with no great biomarkers for screening and early intervention.  Our approach showed high performance for the detection of ovarian cancer and demonstrates that the DELFI platform has broad opportunities for the detection of a variety of human cancers.  

×

Add Names/PO on Receipt

Apply to Speak at PMWC Silicon Valley by NOV. 7TH

The PMWC team will reply back to a suitable company/topic with an official request for talk/speaker details.

Contact Us:

Fields marked with an * are required 

Contact Us:

Fields marked with an * are required 

Discover What's Next in Precision Medicine!

Join our community today for the latest news, exclusive interviews, and unique insights from world-renowned speakers and experts


Contact Us:

Fields marked with an * are required 

Discount also depends on group size. The bigger group – the bigger discount.

Trouble Registering

Fields marked with an * are required

Stay Tuned For More Information.

Sign up for occasional updates on upcoming conferences, news, and other information. 

Get Updates:

Submit to Speak in the PMWC Showcase

Fields marked with an * are required